Ethan Basch

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
    Ethan Basch
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC EB, BBR, AVB Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC EB, BBR, AVB Department of Epidemiology and Biostatistics, Health Outcomes Research Group EB, LS, LR and Department of Psychiatry and Behavioral Sciences JH, TMA, Memorial Sloan Kettering Cancer Center, New York, NY Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences SAM, SBC, Division of Cancer Prevention LMM, NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program AD, Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention AMO, DSG, JK, and Investigational Drug Branch, Cancer Therapy Evaluation Program AC, National Cancer Institute, Bethesda, MD Division of Health Sciences Research, College of Medicine, Mayo Clinic Arizona, Scottsdale, Unidad de Salud Respiratoria
    J Natl Cancer Inst 106:. 2014
  2. pmc Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Clin Trials 13:331-7. 2016
  3. pmc Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
    Ethan Basch
    Ethan Basch, Mark G Kris, Howard I Scher, Clifford A Hudis, Paul Sabbatini, Lauren Rogak, Thomas M Atkinson, Joanne F Chou, Dorothy Dulko, Laura Sit, Michael Fruscione, and Deborah Schrag, Memorial Sloan Kettering Cancer Center, New York, NY Ethan Basch, Allison M Deal, and Antonia V Bennett, University of North Carolina, Chapel Hill, NC Amylou C Dueck, Mayo Clinic, Scottsdale, AZ Allison Barz, Children s Hospital of Philadelphia, Philadelphia, PA Paul Novotny and Jeff A Sloan, Mayo Clinic, Rochester, MN and Deborah Schrag, Dana Farber Harvard Cancer Center, Boston, MA
    J Clin Oncol 34:557-65. 2016
  4. doi request reprint Methods for Developing Patient-Reported Outcome-Based Performance Measures (PRO-PMs)
    Ethan Basch
    University of North Carolina, Chapel Hill, NC, USA Electronic address
    Value Health 18:493-504. 2015
  5. doi request reprint Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort
    Ethan Basch
    Cancer Outcomes Research Program, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA Electronic address
    Eur Urol 67:310-8. 2015
  6. pmc Patient-reported outcomes in clinical trials of rare diseases
    Ethan Basch
    Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    J Gen Intern Med 29:S801-3. 2014
  7. doi request reprint Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
    Ethan Basch
    Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Electronic address
    Lancet Oncol 14:1193-9. 2013
  8. doi request reprint New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment
    Ethan Basch
    Departments of Medicine and Public Health, University of North Carolina, Chapel Hill, North Carolina 97514 email
    Annu Rev Med 65:307-17. 2014
  9. pmc Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy
    Timothy J Judson
    Weill Cornell Medical College, New York, NY, USA
    J Clin Oncol 31:2580-5. 2013
  10. ncbi request reprint Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, and the Office of the Physician in Chief, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5374-80. 2007

Detail Information

Publications58

  1. pmc Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
    Ethan Basch
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC EB, BBR, AVB Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC EB, BBR, AVB Department of Epidemiology and Biostatistics, Health Outcomes Research Group EB, LS, LR and Department of Psychiatry and Behavioral Sciences JH, TMA, Memorial Sloan Kettering Cancer Center, New York, NY Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences SAM, SBC, Division of Cancer Prevention LMM, NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program AD, Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention AMO, DSG, JK, and Investigational Drug Branch, Cancer Therapy Evaluation Program AC, National Cancer Institute, Bethesda, MD Division of Health Sciences Research, College of Medicine, Mayo Clinic Arizona, Scottsdale, Unidad de Salud Respiratoria
    J Natl Cancer Inst 106:. 2014
    ..It is envisioned that the PRO-CTCAE will enhance the precision and patient-centeredness of adverse event reporting in cancer clinical research. ..
  2. pmc Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Clin Trials 13:331-7. 2016
    ....
  3. pmc Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
    Ethan Basch
    Ethan Basch, Mark G Kris, Howard I Scher, Clifford A Hudis, Paul Sabbatini, Lauren Rogak, Thomas M Atkinson, Joanne F Chou, Dorothy Dulko, Laura Sit, Michael Fruscione, and Deborah Schrag, Memorial Sloan Kettering Cancer Center, New York, NY Ethan Basch, Allison M Deal, and Antonia V Bennett, University of North Carolina, Chapel Hill, NC Amylou C Dueck, Mayo Clinic, Scottsdale, AZ Allison Barz, Children s Hospital of Philadelphia, Philadelphia, PA Paul Novotny and Jeff A Sloan, Mayo Clinic, Rochester, MN and Deborah Schrag, Dana Farber Harvard Cancer Center, Boston, MA
    J Clin Oncol 34:557-65. 2016
    ..There is growing interest to enhance symptom monitoring during routine cancer care using patient-reported outcomes, but evidence of impact on clinical outcomes is limited...
  4. doi request reprint Methods for Developing Patient-Reported Outcome-Based Performance Measures (PRO-PMs)
    Ethan Basch
    University of North Carolina, Chapel Hill, NC, USA Electronic address
    Value Health 18:493-504. 2015
    ..To recommend methods for assessing quality of care via patient-reported outcome-based performance measures (PRO-PMs) of symptoms, functional status, and quality of life...
  5. doi request reprint Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort
    Ethan Basch
    Cancer Outcomes Research Program, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA Electronic address
    Eur Urol 67:310-8. 2015
    ..Pain negatively affects quality of life for cancer patients. Preliminary data in metastatic castration-resistant prostate cancer (mCRPC) suggested a benefit of the oral tyrosine kinase inhibitor cabozantinib to pain palliation...
  6. pmc Patient-reported outcomes in clinical trials of rare diseases
    Ethan Basch
    Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    J Gen Intern Med 29:S801-3. 2014
    ..The overall goal of PRO measurement is to understand the patient experience and it provides an essential part of evaluating the impact of disease and treatment. ..
  7. doi request reprint Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
    Ethan Basch
    Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Electronic address
    Lancet Oncol 14:1193-9. 2013
    ..We describe analyses of data for patient-reported pain and functional status in a preplanned interim analysis of a phase 3 trial...
  8. doi request reprint New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment
    Ethan Basch
    Departments of Medicine and Public Health, University of North Carolina, Chapel Hill, North Carolina 97514 email
    Annu Rev Med 65:307-17. 2014
    ..These challenges have been surmounted in limited initiatives and now must be translated to larger implementations. ..
  9. pmc Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy
    Timothy J Judson
    Weill Cornell Medical College, New York, NY, USA
    J Clin Oncol 31:2580-5. 2013
    ..Prior evidence suggests good patient compliance with reporting at scheduled clinic visits, but there is limited evidence about compliance with long-term longitudinal reporting between visits...
  10. ncbi request reprint Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, and the Office of the Physician in Chief, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5374-80. 2007
    ..In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly...
  11. pmc Reliability of adverse symptom event reporting by clinicians
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave, 7th Floor, New York, NY 10022, USA
    Qual Life Res 21:1159-64. 2012
    ..The purpose of this study was to assess the reliability of adverse event reporting of different clinicians for the same patient for the same visit...
  12. pmc Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes
    Ethan Basch
    Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10065, USA
    J Natl Cancer Inst 101:1624-32. 2009
    ..Patient self-reporting has been proposed as an additional data source, but the implications of such a shift are not understood...
  13. pmc Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave, 7th Floor, New York, NY 10022, USA
    Pain Med 13:1417-24. 2012
    ..g., mood) and activity (e.g., work) interference. The purpose of this analysis was to confirm this affective/activity interference dichotomy...
  14. pmc Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities
    Ethan Basch
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Med Inform Assoc 14:264-8. 2007
    ..Ongoing multi-center research will evaluate the impact of this approach on clinical and administrative outcomes...
  15. pmc Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO
    Antonia V Bennett
    Department of Health Policy and Management, University of North Carolina at Chapel Hill, Campus Box 7411, Chapel Hill, NC, 27599, USA
    Health Qual Life Outcomes 14:24. 2016
    ....
  16. doi request reprint Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective
    Ethan Basch
    Cancer Outcomes Research Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    Cancer 120:761-7. 2014
    ..The purpose of this article is to identify common challenges and key design strategies when measuring pain palliation in antitumor therapy clinical trials that are consistent with PRO Guidance principles...
  17. pmc Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI)
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Pain Symptom Manage 41:558-65. 2011
    ....
  18. pmc The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pain Med 11:337-46. 2010
    ..When finalized, it may provide a blueprint for evaluations of PRO measures that can be considered by sponsors and investigators involved in PRO research and drug registration trials...
  19. pmc The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave, 7th Floor, New York, NY, 10022, USA
    Support Care Cancer 24:3669-76. 2016
    ..The aim of this review was to summarize the empirically reported association between analogous CTCAE and PRO ratings...
  20. pmc Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials
    Bryce B Reeve
    Affiliations of authors Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC BBR, EB Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD SAM Division of Cancer Prevention, National Cancer Institute, Bethesda, MD LMM and AMO Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD AMD Division of Health Sciences Research, Mayo Clinic, Scottsdale, AZ ACD Feinberg School of Medicine, Northwestern University, Chicago, IL DC Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA CMR, DWB Department of General Oncology, MD Anderson Cancer Center, Houston, TX MJF Mayo Clinic Breast SPORE, Rochester, MN CCh Department of Psychological Research, The Netherlands Cancer Institute, Amsterdam, The Netherlands NKA Quality of Life Department, European Organization for the Research and Treatment of Cancer, Brussels, Belgium CCo
    J Natl Cancer Inst 106:. 2014
    ..We report the results of an evidence-synthesis and consensus-building effort that culminated in recommendations for core symptoms to be measured in adult cancer clinical trials that include a patient-reported outcome (PRO)...
  21. doi request reprint Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology
    Ethan Basch
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:4249-55. 2012
    ....
  22. pmc Comparison of seven-day and repeated 24-hour recall of symptoms in the first 100 days after hematopoietic cell transplantation
    William A Wood
    Lineberger Comprehensive Cancer Center, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Electronic address
    J Pain Symptom Manage 49:513-20. 2015
    ..Patient-reported outcomes (PROs) provide a way to understand the effects of hematopoietic cell transplantation (HCT)-related stress on patients' lives. We previously reported that weekly collection of PROs is feasible...
  23. doi request reprint Antiemetics: American Society of Clinical Oncology Focused Guideline Update
    Paul J Hesketh
    Paul J Hesketh, Lahey Hospital and Medical Center, Burlington, MA Kari Bohlke and Mark R Somerfield, American Society of Clinical Oncology, Alexandria Michael A Danso, Virginia Oncology Associates, Norfolk and Virginia Beach, VA Gary H Lyman, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC Maurice Chesney, Patient Representative, Saunderstown, RI Rebecca Anne Clark Snow, University of Kansas Cancer Center, Westwood, KS Karin Jordan, University Hospital, Martin Luther University Halle Wittenberg, Halle, Germany and Mark G Kris, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 34:381-6. 2016
    ....
  24. doi request reprint An evidence-based systematic review of gymnema (Gymnema sylvestre R. Br.) by the Natural Standard Research Collaboration
    Catherine Ulbricht
    Massachusetts General Hospital, Boston, Massachusetts, USA
    J Diet Suppl 8:311-30. 2011
    ..Br.), including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing...
  25. pmc Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Amylou C Dueck
    Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona
    JAMA Oncol 1:1051-9. 2015
    ..To integrate the patient perspective into adverse event reporting, the National Cancer Institute developed a patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)...
  26. pmc Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
    Howard I Scher
    Howard I Scher, Michael J Morris, Dana E Rathkopf, and Susan F Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College David Nanus, NewYork Presbyterian Weill Cornell Medical Center Lawrence W Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY Walter M Stadler, University of Chicago Medicine, Chicago, IL Celestina Higano and Peter S Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC Emmanual S Antonarakis and Michael A Carducci, Johns Hopkins University School of Medicine, Baltimore, MD Tomasz M Beer, Oregon Health and Science University, Portland, OR Paul G Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA Daniel J George, Susan Halabi, and Andrew J Armstrong, Duke University and Duke Cancer Institute, Durham, NC Elisabeth I Heath, Wayne State University Karmanos Cancer Institute, Detroit and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, 1006 EA Amsterdam
    J Clin Oncol 34:1402-18. 2016
    ....
  27. pmc Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave, 7th Floor, New York, NY, 10022, USA
    J Cancer Res Clin Oncol . 2017
    ....
  28. pmc Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Jennifer L Hay
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave, 7th Floor, New York, NY, 10022, USA
    Qual Life Res 23:257-69. 2014
    ..This study contributes content validity evidence of the PRO-CTCAE by incorporating cancer patient input of the relevance and comprehensiveness of the item library...
  29. pmc Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303)
    Dorothy Romanus
    Massachusetts General Hospital, Harvard School of Public Health, Boston, Massachusetts, USA
    J Pain Symptom Manage 43:205-17. 2012
    ..Gemcitabine for advanced pancreatic cancer (APC) is palliative and the prognosis is poor, making health-related quality of life (HRQOL) particularly important...
  30. doi request reprint Electronic patient-reported outcome systems in oncology clinical practice
    Antonia V Bennett
    Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    CA Cancer J Clin 62:337-47. 2012
    ..ePRO systems enable regular monitoring of patient symptoms, function, and needs, and can enhance the efficiency and quality of care as well as communication with patients...
  31. pmc Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure
    Angela K Green
    UNC Lineberger Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, and Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 20:516-22. 2015
    ....
  32. pmc Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation
    William A Wood
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA
    Biol Blood Marrow Transplant 19:450-9. 2013
    ..Future studies in larger populations to explore predictive models using frequent PRO data for outcomes, including long-term HRQOL and survival, are warranted...
  33. doi request reprint Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy
    Shari Damast
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Int J Radiat Oncol Biol Phys 84:e187-93. 2012
    ....
  34. ncbi request reprint An evidence-based systematic review of Aloe vera by the natural standard research collaboration
    Catherine Ulbricht
    Massachusetts General Hospital, Boston, MA, USA
    J Herb Pharmacother 7:279-323. 2007
    ..An evidence-based systematic review including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing...
  35. pmc Antiemetics: American Society of Clinical Oncology clinical practice guideline update
    Ethan Basch
    Memorial Sloan Kettering Cancer Center, New York, USA
    J Clin Oncol 29:4189-98. 2011
    ..To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology...
  36. pmc End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 29:3695-704. 2011
    ..We also discuss circulating tumor cells measured with the CellSearch assay, recently cleared by the FDA for monitoring CRPC...
  37. pmc Evaluation of mode equivalence of the MSKCC Bowel Function Instrument, LASA Quality of Life, and Subjective Significance Questionnaire items administered by Web, interactive voice response system (IVRS), and paper
    Antonia V Bennett
    UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Qual Life Res 25:1123-30. 2016
    ..To assess the equivalence of patient-reported outcome (PRO) survey responses across Web, interactive voice response system (IVRS), and paper modes of administration...
  38. pmc Review of electronic patient-reported outcomes systems used in cancer clinical care
    Roxanne E Jensen
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Duke Comprehensive Cancer Center, Duke University Medical Center, Durham Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC and Health Outcomes Group, Memorial Sloan Kettering Cancer Center, New York, NY
    J Oncol Pract 10:e215-22. 2014
    ....
  39. doi request reprint Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology
    Jyoti D Patel
    Jyoti D Patel, Northwestern University Blasé Polite, University of Chicago Medicine, Chicago, IL Lada Krilov, American Society of Clinical Oncology, Alexandria, VA Sylvia Adams and William L Carroll, New York University Cancer Institute Carol Aghajanian, Mark G Kris, and Gary K Schwartz, Memorial Sloan Kettering Cancer Center, New York, NY Ethan Basch, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC Marcia S Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA Marcos de Lima and Mark R Gilbert, University of Texas MD Anderson Cancer Center, Houston Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX John L Marshall, Lombardi Cancer Center, Washington, DC Gregory A Masters, Helen F Graham Cancer Center, Newark, DE Steven J O Day, Beverly Hills Health Center, Beverly Hills, CA Sunil Sharma, Huntsman Cancer Institute, Salt Lake City, UT Nicholas J Vogelzang, US Oncology Research, Comprehensive Cancer Centers of Nevada, Brazil
    J Clin Oncol 32:129-60. 2014
    ..More importantly, I hope the pride you feel motivates you to help us accelerate the pace of scientific advancement. Clifford A. Hudis, MD, FACP President American Society of Clinical Oncology...
  40. pmc Antiemetics: american society of clinical oncology clinical practice guideline update
    Ethan Basch
    Memorial Sloan Kettering Cancer Center, New York, NY Lahey Clinic Medical Center, Burlington, MA American Society of Clinical Oncology, Alexandria, VA Duke University, Durham, NC
    J Oncol Pract 7:395-8. 2011
    ..ASCO's update to its antiemetics guideline now includes an evaluation of evidence on complementary antiemetic therapy...
  41. ncbi request reprint Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 7:903-9. 2006
    ..We aimed to compare the reporting of symptom severity reported by patients and clinicians...
  42. doi request reprint An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the Natural Standard Research Collaboration
    Catherine Ulbricht
    1Massachusetts General Hospital, Boston, MA, USA
    J Diet Suppl 11:80-120. 2014
    ..This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing...
  43. doi request reprint An evidence-based systematic review of vitamin A by the natural standard research collaboration
    Catherine Ulbricht
    Massachusetts General Hospital, Boston, Massachusetts, USA
    J Diet Suppl 9:299-416. 2012
    ..This paper includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing...
  44. ncbi request reprint Patient online self-reporting of toxicity symptoms during chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, New York, NY 10021, USA
    J Clin Oncol 23:3552-61. 2005
    ..Currently, clinicians collect symptom information via complex and often inefficient mechanisms, but there is growing interest in collecting outcome information directly from patients...
  45. pmc Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials
    Ethan Basch
    Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Ther 38:821-30. 2016
    ..However, there are currently no standard recommended approaches for integrating patient-reported AE measures into trials...
  46. doi request reprint Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the Patient
    Ethan Basch
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
    JAMA Oncol 1:375-9. 2015
    ..FDA has begun implementing several of these recommendations. ..
  47. pmc Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study
    Victoria S Blinder
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:1664-74. 2012
    ..We set out to compare the trajectories of low-income Latina and non-Latina white survivors and to identify correlates of employment status...
  48. pmc Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings
    Tracy L Rose
    Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
    Urol Oncol 33:386.e1-6. 2015
    ..This study examines if administration of NAC in the community is associated with differences in type of NAC received, pathologic response rate (pT0), and time to cystectomy as compared to NAC administered at an AMC...
  49. pmc Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  50. pmc Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline
    Ethan Basch
    Ethan Basch, Ronald C Chen, and Stacie B Dusetzina, University of North Carolina, Chapel Hill Derek Raghavan, Carolinas Health Care Levine Cancer Institute, Charlotte, NC D Andrew Loblaw, Odette Cancer Centre, Sunnybrook Health Sciences Centre Ted Wootton, Patient Representatives, Toronto Sebastian Hotte and Cindy Walker Dilks, McMaster University Cindy Walker Dilks, Cancer Care Ontario, Hamilton Eric Winquist, London Health Sciences Centre, London, Ontario Fred Saad, University of Montreal, Montreal, Quebec, Canada Thomas K Oliver and R Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA Michael Carducci, Johns Hopkins University, Baltimore, MD James N Frame, Charleston Area Medical Center Health Systems, Charleston, WV Kristina Garrels, Private Practice, Fargo, ND Michael W Kattan, Cleveland Clinic, Cleveland, OH Mary Ellen Taplin, Dana Farber Cancer Institute, Boston, MA James Williams
    J Clin Oncol 32:3436-48. 2014
    ..To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC)...
  51. pmc The project data sphere initiative: accelerating cancer research by sharing data
    Angela K Green
    UNC Lineberger Comprehensive Cancer Center, School of Medicine, Division of Hematology and Oncology, Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, and Gillings School of Global Public Health, Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 20:464-e20. 2015
    ..e., controls). Both nationally and internationally, a variety of stakeholders have pursued data-sharing efforts to make individual patient-level clinical trial data available to the scientific research community...
  52. doi request reprint Emerging uses of patient generated health data in clinical research
    William A Wood
    Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA Electronic address
    Mol Oncol 9:1018-24. 2015
    ..With successful integration, PGHD can catalyze the application of "big data" to cancer clinical research, creating both "n of 1" and population-level observations, and generating new insights into the nature of health and disease. ..
  53. pmc A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group
    Amy P Abernethy
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Palliat Med 13:1407-13. 2010
    ....
  54. doi request reprint Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data
    Ethan Basch
    a Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Expert Opin Drug Discov 11:753-8. 2016
    ..PRO measures can be included in any phase of product development as primary, secondary, or exploratory endpoints to understand the impact of treatment on the patient experience...
  55. pmc The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave, 7th Floor, New York, NY, 10022, USA
    Support Care Cancer 23:3645-52. 2015
    ..Thus, the purpose of this study was to conduct a systematic review of the level of association between PRO and FPS measures to determine their differential or combined utility...
  56. doi request reprint A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
    Mario E Lacouture
    Dermatology Service, Rockefeller Outpatient Pavilion, Memorial Sloan Kettering 53rd Street, 160 East 53rd Street, New York, NY 10022, USA
    Support Care Cancer 18:509-22. 2010
    ..We believe a class-specific grading scale is needed to help standardize assessment and improve reporting of EGFRI-associated dermatologic AEs...
  57. ncbi request reprint Maitake mushroom (Grifola frondosa): systematic review by the natural standard research collaboration
    Catherine Ulbricht
    Massachusetts General Hospital, Boston, MA, USA
    J Soc Integr Oncol 7:66-72. 2009
    ..Despite the lack of scientific evidence, maitake mushroom remains a popular agent in commercial products. Future randomized controlled trials are warranted...
  58. pmc Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion
    Ethan Basch
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 30:3020-5. 2012
    ..This PCO addresses the role of prostate-specific antigen (PSA) testing in the screening of men for prostate cancer...